Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Fast Track Articles
  5. Fast Track Article
image of Asymptomatic Hypocalcemia Related to Denosumab Administration in Bone-Metastatic Patient Affected by Colorectal Cancer: A Case Report
file format pdf download PDF

Abstract

Background

Denosumab, a fully humanized monoclonal neutralizing antibody inhibiting the RANK/RANKL/OPG signaling pathway, is widely used for treating patients with bone metastases. However, its use in cancer patients with bone metastases is burdened by the risk of all grades of hypocalcemia, with the severe grade being rare. In the literature, several cases of severe symptomatic hypocalcemia have been reported, particularly in patients with breast and prostate cancers. In this report, we present a rare case of asymptomatic hypocalcemia in a 78 years-old patient with sigmoid cancer and bone metastases.

Case Presentation

Hypocalcemia was detected two weeks after the first denosumab administration, during routine biochemical evaluation. The patient reported only a mild nonspecific paresthesia after medical questioning, without relevant clinical symptoms. Despite the severity of the hypocalcemia, serum calcium levels began to improve after a short period of low-dose calcium and calcitriol therapy, though complete stabilization and normalization occurred after several weeks.

Conclusion

This case highlight the importance to consider severe paucisymptomatic or asymptomatic hypocalcemia as a possible side effect in bone-metastatic patients treated with denosumab. It is advisable to monitor serum calcium levels even in the absence of typical hypocalcemia-related symptoms.

© 2024 The Author(s). Published by Bentham Science Publishers
© 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303347379241107095529
2024-12-05
2025-01-18

  • From This Site

    /content/journals/emiddt/10.2174/0118715303347379241107095529
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/10.2174/0118715303347379241107095529/BMS-EMIDDT-2024-324.html?itemId=/content/journals/emiddt/10.2174/0118715303347379241107095529&mimeType=html&fmt=ahah

References

  1. Kostenuik P.J. Nguyen H.Q. McCabe J. Warmington K.S. Kurahara C. Sun N. Chen C. Li L. Cattley R.C. Van G. Scully S. Elliott R. Grisanti M. Morony S. Tan H.L. Asuncion F. Li X. Ominsky M.S. Stolina M. Dwyer D. Dougall W.C. Hawkins N. Boyle W.J. Simonet W.S. Sullivan J.K. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J. Bone Miner. Res. 2009 24 2 182 195 10.1359/jbmr.081112 19016581
    [Google Scholar]
  2. Kendler D.L. Cosman F. Stad R.K. Ferrari S. Denosumab in the treatment of osteoporosis: 10 years later: A narrative review. Adv. Ther. 2022 39 1 58 74 10.1007/s12325‑021‑01936‑y 34762286
    [Google Scholar]
  3. Coleman R. Hadji P. Body J.J. Santini D. Chow E. Terpos E. Oudard S. Bruland Ø. Flamen P. Kurth A. Van Poznak C. Aapro M. Jordan K. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. 2020 31 12 1650 1663 10.1016/j.annonc.2020.07.019 32801018
    [Google Scholar]
  4. Takahashi S. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer. J. Bone Miner. Metab. 2023 41 3 307 316 10.1007/s00774‑023‑01414‑1 37036530
    [Google Scholar]
  5. Lipton A. Fizazi K. Stopeck A.T. Henry D.H. Brown J.E. Yardley D.A. Richardson G.E. Siena S. Maroto P. Clemens M. Bilynskyy B. Charu V. Beuzeboc P. Rader M. Viniegra M. Saad F. Ke C. Braun A. Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur. J. Cancer 2012 48 16 3082 3092 10.1016/j.ejca.2012.08.002 22975218
    [Google Scholar]
  6. Nasser S.M. Sahal A. Hamad A. Elazzazy S. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study. J. Oncol. Pharm. Pract. 2019 25 8 1846 1852 10.1177/1078155218820927 31694497
    [Google Scholar]
  7. Fizazi K. Carducci M. Smith M. Damião R. Brown J. Karsh L. Milecki P. Shore N. Rader M. Wang H. Jiang Q. Tadros S. Dansey R. Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011 377 9768 813 822 10.1016/S0140‑6736(10)62344‑6 21353695
    [Google Scholar]
  8. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006 12 20 6243s 6249s 10.1158/1078‑0432.CCR‑06‑0931 17062708
    [Google Scholar]
  9. Steger G.G. Bartsch R. Denosumab for the treatment of bone metastases in breast cancer: Evidence and opinion. Ther. Adv. Med. Oncol. 2011 3 5 233 243 10.1177/1758834011412656 21957430
    [Google Scholar]
  10. Tsvetov G. Amitai O. Shochat T. Shimon I. Akirov A. Cohen T. Denosumab-induced hypocalcemia in patients with osteoporosis: Can you know who will get low? Osteoporos. Int. 2020 31 4 655 665 10.1007/s00198‑019‑05261‑7 31838550
    [Google Scholar]
  11. Huynh A.L.H. Baker S.T. Stewardson A.J. Johnson D.F. Denosumab‐associated hypocalcaemia: Incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol. Drug Saf. 2016 25 11 1274 1278 10.1002/pds.4045 27255807
    [Google Scholar]
  12. Verzicco I. Regolisti G. Quaini F. Bocchi P. Brusasco I. Ferrari M. Passeri G. Cannone V. Coghi P. Fiaccadori E. Vignali A. Volpi R. Cabassi A. Electrolyte disorders induced by antineoplastic drugs. Front. Oncol. 2020 10 779 10.3389/fonc.2020.00779 32509580
    [Google Scholar]
  13. Fakih M.G. Wilding G. Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin. Colorectal Cancer 2006 6 2 152 156 10.3816/CCC.2006.n.033 16945172
    [Google Scholar]
  14. Tejpar S. Piessevaux H. Claes K. Piront P. Hoenderop J.G.J. Verslype C. Van Cutsem E. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study. Lancet Oncol. 2007 8 5 387 394 10.1016/S1470‑2045(07)70108‑0 17466895
    [Google Scholar]
  15. Tsujii T. Ogaki T. Nakae K. Imai K. Kise D. Tada S. Ueda H. Moriyama M. Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody. J. Pharm. Health Care Sci. 2016 2 1 23 10.1186/s40780‑016‑0060‑9 27688901
    [Google Scholar]
  16. Witteveen J.E. van Thiel S. Romijn J.A. Hamdy N.A.T. Therapy of endocrine disease: Hungry bone syndrome: Still a challenge in the post-operative management of primary hyperparathyroidism: A systematic review of the literature. Eur. J. Endocrinol. 2013 168 3 R45 R53 10.1530/EJE‑12‑0528 23152439
    [Google Scholar]
  17. Florescu M. Plumb T. Smith-Shull S. Nieman J. Mandalapu P. Islam K.M. Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients. Int. J. Nephrol. Renovasc. Dis. 2014 7 183 190 10.2147/IJNRD.S56995 24868170
    [Google Scholar]
  18. Garla V. V. Salim S. Kovvuru K. R. Subauste A. Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy. BMJ Case Rep. 2018 2018 bcr2018225039 10.1136/bcr‑2018‑225039
    [Google Scholar]
  19. Nakamura Y. Kamimura M. Ikegami S. Mukaiyama K. Uchiyama S. Taguchi A. Kato H. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: A short-term study. BMC Endocr. Disord. 2015 15 1 81 10.1186/s12902‑015‑0077‑3 26666998
    [Google Scholar]
  20. Pittman K. Antill Y.C. Goldrick A. Goh J. de Boer R.H. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac. J. Clin. Oncol. 2017 13 4 266 276 10.1111/ajco.12517 27862983
    [Google Scholar]
  21. Body J.J. Bone H.G. de Boer R.H. Stopeck A. Van Poznak C. Damião R. Fizazi K. Henry D.H. Ibrahim T. Lipton A. Saad F. Shore N. Takano T. Shaywitz A.J. Wang H. Bracco O.L. Braun A. Kostenuik P.J. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur. J. Cancer 2015 51 13 1812 1821 10.1016/j.ejca.2015.05.016 26093811
    [Google Scholar]
  22. Nakamura K. Kaya M. Yanagisawa Y. Yamamoto K. Takayashiki N. Ukita H. Nagura M. Sugiue K. Kitajima M. Hirano K. Ishida H. Onoda C. Kobayashi Y. Nakatani E. Odagiri K. Suzuki T. Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: A multicenter, retrospective, observational study. BMC Cancer 2024 24 1 218 10.1186/s12885‑024‑11942‑2 38360579
    [Google Scholar]
  23. Dadana S. Gundepalli S. Kondapalli A. Severe refractory hypocalcemia caused by denosumab. Cureus 2023 15 6 e39866 37404446
    [Google Scholar]
  24. Aldasouqi S. Glassy C.M. Glassy M.S. Treska A. Caldwell-McMillan M. Gossain V. Asymptomatic severe hypocalcemia secondary to vitamin d deficiency in an elderly patient. Case Rep. Endocrinol. 2011 2011 1 3 10.1155/2011/830952 22937291
    [Google Scholar]
  25. Ajero P.M.E. Belsky J.L. Prawius H.D. Rella V. Chemotherapy-induced hypocalcemia. Endocr. Pract. 2010 16 2 284 290 10.4158/EP09137.RA 19789154
    [Google Scholar]
  26. McCaleb R.V. Johnson J.T. Severe, prolonged, denosumab-induced hypocalcemia with recovery after 111 days of high-dose calcium supplementation. AACE Clin. Case Rep. 2019 5 1 e82 e85 10.4158/ACCR‑2018‑0295 31967007
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303347379241107095529
Loading
Asymptomatic Hypocalcemia Related to Denosumab Administration in Bone-Metastatic Patient Affected by Colorectal Cancer: A Case Report
Bentham Science Publishers ; https://doi.org/10.2174/0118715303347379241107095529
/content/journals/emiddt/10.2174/0118715303347379241107095529
/content/journals/emiddt/10.2174/0118715303347379241107095529
Loading

Data & Media loading...


  • Article Type:     Case Report
Keywords: bone metastases ; hypocalcemia ; Denosumab ; cancer ; case report

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test